About
Definium Therapeutics (formerly MindMed) is a clinical-stage biotech company developing psychedelic-inspired medicines, including proprietary formulations of LSD and MDMA enantiomers, to treat mental health disorders such as depression, anxiety, PTSD, and autism spectrum disorder.
Explore Definium Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.